7Baggers
Quarterly
Annual
    Unit: USD2033-12-31 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 
      
    		                          
      cash flows from operating activities
    		                          
      shareholders' net income
    		                          
      adjustments to reconcile shareholders' net income
    		                          
      to net cash from operating activities
    		                          
      equity in income of subsidiaries
    		                          
      dividends received from subsidiaries
    		                          
      other liabilities
    		                          
      other
    		180,000,000 43,000,000 157,000,000 260,000,000 430,000,000 164,000,000 61,000,000 18,000,000 133,000,000 104,000,000 244,000,000 96,000,000 48,000,000 -63,000,000 -93,135,000,000 93,280,000,000 104,000,000 84,000,000 129,000,000 81,000,000 243,000,000 144,000,000 -237,000,000 68,000,000 106,000,000 83,000,000 
      net cash from operating activities
    		-1,613,000,000 3,418,000,000 -1,886,000,000 1,920,000,000 46,000,000 265,000,000 4,840,000,000 2,826,000,000 2,492,000,000 5,028,000,000 2,099,000,000 3,283,000,000 1,244,000,000 2,030,000,000 -29,158,865,000,000 29,165,259,000,000 -296,000,000 1,093,000,000 4,294,000,000 895,000,000 3,274,000,000 1,887,000,000 -4,989,000,000 2,461,000,000 1,039,000,000 3,192,000,000 
      cash flows from investing activities
    		                          
      net change in amounts due from affiliates
    		                          
      net proceeds from short-term investments sold
    		                          
      net cash from investing activities
    		4,609,000,000 -4,387,000,000 -797,000,000 1,197,000,000 -776,000,000 -640,000,000 -495,000,000 -1,337,000,000 -414,000,000 -2,983,000,000 -616,000,000           -269,000,000    475,000,000 
      cash flows from financing activities
    		                          
      net change in amounts due to affiliates
    		                          
      net change in commercial paper
    		                          
      repayment of long-term debt
    		-1,179,000,000 -43,000,000 -900,000,000 -700,000,000 0 -790,000,000 -2,210,000,000 -2,887,000,000 0 -80,000,000     0 0 -379,000,000 -4,199,000,000 -1,150,000,000 -2,099,000,000 -589,000,000 -4,209,000,000 338,000,000 -600,000,000 -1,740,000,000 -1,000,000,000 
      net proceeds on issuance of long-term debt
    		-2,970,000,000    0 0 4,462,000,000 0 0 1,491,000,000     -42,599,205,000,000 42,599,205,000,000 -2,000,000 4,262,000,000 0 0 -5,000,000 3,470,000,000     
      issuance of common stock
    		9,000,000 37,000,000 72,000,000 69,000,000 62,000,000 40,000,000 181,000,000 54,000,000 29,000,000 30,000,000 72,000,000 100,000,000 124,000,000 93,000,000 -300,913,000,000 300,949,000,000 86,000,000 204,000,000 137,000,000 10,000,000 76,000,000 153,000,000 123,000,000 31,000,000 17,000,000 53,000,000 
      common dividends paid
    		                          
      repurchase of common stock
    		336,000,000 0 -1,112,000,000 -1,508,000,000 0 -990,000,000 -4,022,000,000 -624,000,000 -154,000,000 -962,000,000 -1,733,000,000 -3,500,000,000 -1,006,000,000 -1,368,000,000 -1,421,000,000 -2,611,000,000 -916,000,000 -2,794,000,000 -1,690,000,000 -1,028,000,000 -368,000,000 -956,000,000 -447,000,000 -674,000,000 -404,000,000 -462,000,000 
      tax withholding on stock compensation and other
    		                          
      net cash from financing activities
    		77,000,000 2,659,000,000 -1,333,000,000 -3,681,000,000 439,000,000 -2,309,000,000 -2,529,000,000 -2,572,000,000 -435,000,000 -37,000,000 -2,636,000,000            3,564,000,000    
      net increase in cash, cash equivalents and restricted cash
    		   -555,000,000 -273,000,000 -2,687,000,000 1,807,000,000 -1,090,000,000 1,647,000,000 2,013,000,000 -1,141,000,000        4,041,000,000 -1,717,000,000 2,747,000,000 -237,000,000     
      cash, cash equivalents and restricted cash, beginning of year
    		                          
      cash, cash equivalents and restricted cash, end of year
    		                          
      noncash investing and financing activities:
    		                          
      net amounts due from affiliates settled through capital transactions
    		                          
      principal
    		                          
      1,000 million
    		                          
      750 million
    		                          
      1,250 million
    		                          
      1,500 million
    		                          
      debt extinguishment costs
    		              -141,058,000,000 141,058,000,000 10,000,000 131,000,000 0 0 14,000,000 185,000,000     
      payments for debt extinguishment
    		              0 0 -10,000,000 -126,000,000 0 0 -20,000,000 -192,000,000     
      net amounts due to/(from) affiliates settled through capital transactions
    		                          
      700 million
    		                          
      800 million
    		                          
      net income
    		 1,973,000,000 1,632,000,000 1,409,000,000 825,000,000 1,629,000,000 -212,000,000 1,449,000,000 1,510,000,000 1,306,000,000 1,198,000,000 2,778,000,000 1,572,000,000 1,198,000,000 -42,818,932,000,000 42,821,700,000,000 1,476,000,000 1,171,000,000 4,142,000,000 1,398,000,000 1,760,000,000 1,189,000,000  1,354,000,000 1,410,000,000 1,372,000,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                          
      depreciation and amortization
    		 697,000,000 682,000,000 674,000,000 650,000,000 738,000,000 741,000,000 766,000,000 755,000,000 749,000,000 735,000,000 726,000,000 759,000,000 717,000,000 -21,799,166,000,000 21,800,643,000,000 731,000,000 715,000,000 713,000,000 702,000,000 694,000,000 693,000,000  913,000,000 914,000,000 897,000,000 
      investment (gains) losses
    		 -26,000,000                         
      deferred income tax benefit
    		 118,000,000 -76,000,000 -216,000,000 -152,000,000 -97,000,000 -102,000,000 -96,000,000 -99,000,000 -108,000,000 -180,000,000                
      (gain) loss on sale of businesses
    		 -38,000,000 0 -41,000,000                       
      net changes in assets and liabilities, net of non-operating effects:
    		                          
      accounts receivable
    		 -513,000,000 -4,193,000,000 -2,205,000,000 -3,287,000,000 -4,626,000,000 -2,687,000,000 -772,000,000 -665,000,000 -479,000,000 102,000,000 430,000,000 -1,786,000,000 -983,000,000 1,196,000,000 -806,000,000 -1,813,000,000 -1,420,000,000 1,314,000,000 -689,000,000 -1,065,000,000 -1,056,000,000  -6,000,000 -769,000,000 -396,000,000 
      inventories
    		 334,000,000 -791,000,000 1,517,000,000 105,000,000 -543,000,000 1,015,000,000 97,000,000 -303,000,000 566,000,000 -759,000,000 -237,000,000 -281,000,000 222,000,000 -2,012,000,000 1,331,000,000 -123,000,000 247,000,000 -509,000,000 55,000,000 -146,000,000 96,000,000  137,000,000 84,000,000 440,000,000 
      reinsurance recoverable and other assets
    		 -135,000,000 -183,000,000 -219,000,000 201,000,000 -627,000,000 68,000,000 172,000,000 37,000,000 72,000,000 -492,000,000 189,000,000 -178,000,000 443,000,000 -108,000,000 135,000,000 -456,000,000 40,000,000 698,000,000 -496,000,000 238,000,000 -210,000,000  85,000,000 -301,000,000 124,000,000 
      insurance liabilities
    		 -40,000,000 -76,000,000 1,778,000,000 -89,000,000 -657,000,000 532,000,000 -245,000,000 194,000,000 1,533,000,000 -690,000,000 507,000,000 78,000,000 396,000,000 -862,773,000,000 863,063,000,000 234,000,000 443,000,000 101,000,000 257,000,000 142,000,000 341,000,000  293,000,000 -63,000,000 360,000,000 
      pharmacy and other service costs payable
    		 842,000,000 860,000,000 135,000,000 1,159,000,000 3,183,000,000 4,637,000,000 703,000,000 1,008,000,000 539,000,000 392,000,000 244,000,000 1,198,000,000 -74,000,000 -13,570,123,000,000 13,570,961,000,000 708,000,000 415,000,000         
      accounts payable and accrued expenses and other liabilities
    		 163,000,000 154,000,000 -1,174,000,000 -804,000,000 1,053,000,000 -1,068,000,000 699,000,000 -52,000,000 690,000,000 1,349,000,000 359,000,000 -168,000,000 34,000,000 1,334,000,000 232,000,000 -1,006,000,000 -637,000,000 1,378,000,000 -662,000,000 322,000,000 308,000,000  393,000,000 -461,000,000 91,000,000 
      proceeds from investments sold:
    		                          
      debt securities and equity securities
    		 246,000,000 178,000,000 94,000,000 176,000,000 125,000,000 268,000,000 111,000,000 450,000,000 196,000,000 338,000,000 167,000,000 482,000,000 757,000,000 -10,520,008,000,000 10,521,186,000,000 474,000,000 378,000,000 245,000,000 400,000,000 882,000,000 756,000,000     
      investment maturities and repayments:
    		                          
      commercial mortgage loans
    		 108,000,000 5,000,000 85,000,000 42,000,000 33,000,000 4,000,000 4,000,000 78,000,000 4,000,000 25,000,000 4,000,000 4,000,000 65,000,000 -12,534,000,000 12,618,000,000 24,000,000 72,000,000 5,000,000 4,000,000 5,000,000 5,000,000  5,000,000 80,000,000 89,000,000 
      other sales, maturities and repayments
    		 225,000,000 100,000,000 331,000,000 116,000,000 179,000,000 272,000,000 140,000,000 153,000,000 160,000,000 133,000,000 161,000,000 266,000,000 479,000,000 -12,609,150,000,000 12,610,189,000,000 533,000,000 364,000,000 489,000,000 422,000,000 318,000,000 346,000,000  328,000,000 283,000,000 367,000,000 
      investments purchased or originated:
    		                          
      property and equipment purchases
    		 -278,000,000 -285,000,000 -327,000,000 -399,000,000 -370,000,000 -300,000,000 -403,000,000 -397,000,000 -408,000,000 -345,000,000 -338,000,000 -324,000,000 -288,000,000 -304,000,000 -350,000,000 -258,000,000 -242,000,000 -319,000,000 -252,000,000 -256,000,000 -267,000,000  -243,000,000 -303,000,000 -194,000,000 
      acquisitions, net of cash acquired
    		              3,000,000 0   -4,000,000     0   
      divestitures, net of cash sold
    		 0 0 2,346,000,000    -14,000,000 5,000,000 22,000,000 -3,000,000                
      renewable energy tax credit equity investments
    		 -158,000,000 -235,000,000 -92,000,000                       
      deposits and interest credited to contractholder deposit funds
    		 39,000,000 38,000,000 36,000,000 36,000,000 41,000,000 43,000,000 31,000,000 51,000,000 45,000,000 43,000,000 37,000,000 41,000,000 43,000,000 -132,616,000,000 132,673,000,000 49,000,000 47,000,000 254,000,000 240,000,000 262,000,000 267,000,000  233,000,000 251,000,000 247,000,000 
      withdrawals and benefit payments from contractholder deposit funds
    		 -64,000,000 -73,000,000 -64,000,000 -45,000,000 -70,000,000 -65,000,000 -39,000,000 -52,000,000 -48,000,000 -59,000,000 -67,000,000 -45,000,000 -49,000,000 -29,000,000 -43,000,000 -61,000,000 -35,000,000 -243,000,000 -253,000,000 -228,000,000 -255,000,000  -303,000,000 -291,000,000 -251,000,000 
      net change in short-term debt, excluding term loan
    		                          
      net proceeds on issuance of term loan
    		                  0 0       
      repayment of term loan
    		                          
      common stock dividend paid
    		 -402,000,000 -401,000,000 -412,000,000 -390,000,000 -392,000,000 -401,000,000 -362,000,000 -362,000,000 -368,000,000 -334,000,000 -341,000,000 -352,000,000 -357,000,000 -324,000,000 -330,000,000 -342,000,000 -345,000,000         
      effect of foreign currency rate changes on cash, cash equivalents and restricted cash
    		 -5,000,000 26,000,000 9,000,000 18,000,000 -3,000,000 -9,000,000 -7,000,000 4,000,000 5,000,000 12,000,000 -18,000,000 -57,000,000 -23,000,000 -19,000,000 -19,000,000 -1,000,000 -26,000,000 48,000,000 8,000,000 22,000,000 -37,000,000     
      net decrease in cash, cash equivalents and restricted cash
    		 1,685,000,000                         
      cash, cash equivalents and restricted cash january 1,
    		 0 0 8,931,000,000 0 0 8,337,000,000 0 0 5,976,000,000 0 0 0 5,548,000,000 -102,445,166,000,000 102,445,166,000,000 0 10,245,000,000         
      cash, cash equivalents and restricted cash september 30,
    		                          
      cash and cash equivalents reclassified to assets of businesses held for sale
    		    -624,000,000 1,035,000,000 -1,660,000,000      136,000,000 -591,000,000             
      cash, cash equivalents and restricted cash september 30, per consolidated balance sheets
    		                          
      supplemental disclosure of cash information:
    		                          
      income taxes paid, net of refunds
    		 6,000,000 210,000,000 140,000,000 272,000,000 457,000,000 110,000,000 454,000,000 849,000,000 77,000,000 504,000,000 435,000,000 868,000,000 43,000,000 -19,159,168,000,000 19,159,935,000,000 1,351,000,000 122,000,000 429,000,000 1,218,000,000 109,000,000 81,000,000  417,000,000 1,161,000,000 29,000,000 
      interest paid
    		 363,000,000 301,000,000 379,000,000 394,000,000 307,000,000 336,000,000 387,000,000 310,000,000 322,000,000 306,000,000 308,000,000 307,000,000 308,000,000 -9,499,859,000,000 9,500,473,000,000 308,000,000 331,000,000 327,000,000 369,000,000 348,000,000 395,000,000  392,000,000 488,000,000 377,000,000 
      net change in short-term debt
    		  1,187,000,000 -891,000,000 833,000,000 -103,000,000 -364,000,000 1,301,000,000 192,000,000 -9,000,000 -8,000,000 -1,807,000,000 219,000,000 -463,000,000 -1,632,617,000,000 1,633,120,000,000 1,502,000,000 -1,030,000,000 -532,000,000 1,545,000,000 -773,000,000 -180,000,000  142,000,000 427,000,000 -1,048,000,000 
      cash, cash equivalents and restricted cash june 30,
    		                          
      cash, cash equivalents and restricted cash june 30, per consolidated balance sheets
    		                          
      investment losses
    		   2,000,000                       
      cash, cash equivalents and restricted cash, march 31,
    		   8,376,000,000   10,144,000,000   7,989,000,000    5,060,000,000    6,544,000,000    5,174,000,000     
      cash, cash equivalents and restricted cash march 31, per consolidated balance sheets
    		   8,376,000,000   8,484,000,000   7,989,000,000    4,469,000,000    6,544,000,000         
      realized investment losses
    		    921,000,000 48,000,000 1,836,000,000 14,000,000 -26,000,000 56,000,000                 
      loss on sale of businesses
    		    87,000,000 0 19,000,000                    
      cash, cash equivalents and restricted cash, september 30,
    		                          
      cash, cash equivalents and restricted cash, june 30,
    		                          
      gain on sale of businesses
    		          73,000,000                
      realized investment losses (gains)
    		          0        -167,000,000 -32,000,000 -38,000,000 88,000,000     
      cash, cash equivalents and restricted cash, december 31,
    		                          
      cash, cash equivalents and restricted cash december 31, per consolidated balance sheets
    		                          
      deferred policy acquisition costs
    		           -22,000,000 -64,000,000 -41,000,000 -85,000,000 -65,000,000 -57,000,000 -60,000,000 -63,000,000 -67,000,000 -39,000,000 -138,000,000  -63,000,000 -48,000,000 -51,000,000 
      realized investment (gains) losses
    		            95,000,000 319,000,000   -59,000,000 -1,000,000      -51,000,000 -23,000,000 -10,000,000 
      deferred income tax
    		            -29,000,000 -138,000,000 -116,000,000 -24,000,000 -45,000,000 -35,000,000 -46,000,000 -81,000,000 -98,000,000 -161,000,000     
      divestiture, net of cash sold
    		            0 -57,000,000             
      net cash (used in) investing activities
    		            -408,000,000 -324,000,000  -710,000,000 -2,307,000,000 -717,000,000  -938,000,000   433,000,000 -304,000,000   
      net cash (used in) financing activities
    		            -916,000,000 -2,171,000,000 -2,371,000,000 -1,728,000,000 -62,000,000 -4,051,000,000  -1,682,000,000 -312,000,000 -1,818,000,000   -1,773,000,000 -2,534,000,000 
      net (decrease) in cash, cash equivalents and restricted cash
    		            -137,000,000 -488,000,000    -3,701,000,000         
      gain on sale of business
    		                          
      cash reclassified to assets of businesses held for sale
    		                          
      cash reclassified to assets of business held for sale
    		                   -380,000,000 179,000,000 -597,000,000     
      pharmacy and service costs payable
    		                   429,000,000 1,247,000,000 408,000,000  -503,000,000 269,000,000 444,000,000 
      cash, cash equivalents, and restricted cash january 1,
    		                   0 0 5,411,000,000     
      cash, cash equivalents, and restricted cash september 30, per consolidated balance sheets
    		                          
      cash, cash equivalents, and restricted cash june 30, per consolidated balance sheets
    		                          
      cash, cash equivalents, and restricted cash march 31, per consolidated balance sheets
    		                     4,577,000,000     
      shareholders’ net income
    		                          
      adjustments to reconcile shareholders’ net income
    		                          
      short-term investment purchased
    		                          
      proceeds on issuance of commercial paper
    		                          
      net increase in cash and cash equivalents
    		                      -965,000,000 967,000,000 -1,366,000,000 1,121,000,000 
      cash and cash equivalents, beginning of year
    		                          
      cash and cash equivalents, end of year
    		                          
      * as described in note 4 to the consolidated financial statements, on december 20, 2018, old cigna became a wholly-owned subsidiary of cigna, and cigna became the registrant.
    		                          
      deferred income tax (benefit) expense
    		                       -159,000,000 -79,000,000 -162,000,000 
      debt and equity securities
    		                       603,000,000 565,000,000 1,471,000,000 
      effect of foreign currency rate changes on cash and cash equivalents
    		                       -17,000,000 2,000,000 -12,000,000 
      cash and cash equivalents, january 1,
    		                       0 0 3,855,000,000 
      cash and cash equivalents, september 30,
    		                          
      the accompanying notes to the consolidated financial statements (unaudited) are an integral part of these statements.
    		                          
      cash and cash equivalents, june 30,
    		                          
      cash and cash equivalents, march 31,
    		                         4,976,000,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.